| Package | dk.kip.rkkp.fhir.ig.core |
| Resource Type | CodeSystem |
| Id | TreatmentRegimen |
| FHIR Version | R4 |
| Source | https://kip.rkkp.dk/fhir/https://build.fhir.org/ig/KIP-infrastructure/implementation-guide/CodeSystem-TreatmentRegimen.html |
| URL | https://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen |
| Version | 2.12.0 |
| Status | active |
| Date | 2022-07-12T00:00:00+02:00 |
| Name | TreatmentRegimen |
| Title | Treatment regimen |
| Description | Treatment regimen |
| Content | complete |
| ValueSet | |
| TreatmentRegimen | Behandlingsplan |
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: CodeSystem TreatmentRegimen
This case-insensitive code system https://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen defines the following codes:
{
"resourceType": "CodeSystem",
"id": "TreatmentRegimen",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://kip.rkkp.dk/fhir/CodeSystem/TreatmentRegimen",
"version": "2.12.0",
"name": "TreatmentRegimen",
"title": "Treatment regimen",
"status": "active",
"date": "2022-07-12T00:00:00+02:00",
"publisher": "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"contact": [
{
"name": "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"telecom": [
{
"system": "url",
"value": "https://trifork.com"
},
{
"system": "email",
"value": "rbk@trifork.com"
}
]
}
],
"description": "Treatment regimen",
"caseSensitive": false,
"content": "complete",
"count": 37,
"concept": [
{
"code": "toplusfem",
"display": "2+5 eller lign, eks. CT",
"definition": "2+5 eller lign, eks. CT"
},
{
"code": "aida",
"display": "AIDA",
"definition": "AIDA"
},
{
"code": "all_ved",
"display": "ALL vedligehold",
"definition": "ALL vedligehold"
},
{
"code": "atoatra",
"display": "ATO+ATRA",
"definition": "ATO+ATRA"
},
{
"code": "azacitidinmono",
"display": "Azacitidin monoterapi",
"definition": "Azacitidin monoterapi"
},
{
"code": "azacitidinvene",
"display": "Azacitidin-venetoclax",
"definition": "Azacitidin-venetoclax"
},
{
"code": "hydrea",
"display": "Hydrea",
"definition": "Hydrea"
},
{
"code": "hdara_c",
"display": "Hd-Ara-c +- supplement",
"definition": "Hd-Ara-c +- supplement"
},
{
"code": "ade",
"display": "ADE +- supplement",
"definition": "ADE +- supplement"
},
{
"code": "da",
"display": "DA +- supplement",
"definition": "DA +- supplement"
},
{
"code": "da31087",
"display": "DA inkl. 3+10, 3+8, 3+7",
"definition": "DA inkl. 3+10, 3+8, 3+7"
},
{
"code": "da31087my",
"display": "DA inkl. 3+10, 3+8, 3+7 + mylotarg",
"definition": "DA inkl. 3+10, 3+8, 3+7 + mylotarg"
},
{
"code": "da31087mi",
"display": "DA inkl. 3+10, 3+8, 3+7 + midostaurin",
"definition": "DA inkl. 3+10, 3+8, 3+7 + midostaurin"
},
{
"code": "flag",
"display": "FLAG +- supplement",
"definition": "FLAG +- supplement"
},
{
"code": "flagmito",
"display": "FLAG-Ida eller lign inkl FLAG, Mito-FLAG",
"definition": "FLAG-Ida eller lign inkl FLAG, Mito-FLAG"
},
{
"code": "flagmitovene",
"display": "FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax",
"definition": "FLAG-Ida eller lign inkl FLAG, Mito-FLAG + venetoclax"
},
{
"code": "gilteritinib",
"display": "Gilteritinib",
"definition": "Gilteritinib"
},
{
"code": "idarac",
"display": "IdAraC",
"definition": "IdAraC"
},
{
"code": "inotuzumab",
"display": "Inotuzumab ozogamicin",
"definition": "Inotuzumab ozogamicin"
},
{
"code": "mace",
"display": "MACE +- supplement",
"definition": "MACE +- supplement"
},
{
"code": "midac",
"display": "MidAC",
"definition": "MidAC"
},
{
"code": "midostaurin_ved",
"display": "Midostaurin vedligehold",
"definition": "Midostaurin vedligehold"
},
{
"code": "ldara",
"display": "LdARA-C +- supplement",
"definition": "LdARA-C +- supplement"
},
{
"code": "atra",
"display": "ATRA",
"definition": "ATRA"
},
{
"code": "apl_mt",
"display": "APL-vedligeholdsbehandling",
"definition": "APL-vedligeholdsbehandling"
},
{
"code": "azacytidin_supplement",
"display": "5-Azacytidin +- supplement",
"definition": "5-Azacytidin +- supplement"
},
{
"code": "blinatumomab",
"display": "Blinatumomab",
"definition": "Blinatumomab"
},
{
"code": "vyxeos",
"display": "Vyxeos +- supplement",
"definition": "Vyxeos +- supplement"
},
{
"code": "nopho_2008",
"display": "NOPHO-2008",
"definition": "NOPHO-2008"
},
{
"code": "all_mt",
"display": "ALL vedligeholdelsesbehandling",
"definition": "ALL vedligeholdelsesbehandling"
},
{
"code": "other_ikke",
"display": "Anden ikke-intensiv",
"definition": "Anden ikke-intensiv"
},
{
"code": "other_eks",
"display": "Anden eksperimentel",
"definition": "Anden eksperimentel"
},
{
"code": "other_semi",
"display": "Anden semiintensiv (f.eks. Plan B)",
"definition": "Anden semiintensiv (f.eks. Plan B)"
},
{
"code": "other_int",
"display": "Anden intensiv (f.eks. BISHOP, Plan A)",
"definition": "Anden intensiv (f.eks. BISHOP, Plan A)"
},
{
"code": "hyper_cvad",
"display": "Hyper-CVAD",
"definition": "Hyper-CVAD"
},
{
"code": "alltogether_mt",
"display": "ALLtogether",
"definition": "ALLtogether"
},
{
"code": "experimental",
"display": "anden behl incl anden experimentel",
"definition": "anden behl incl anden experimentel"
}
]
}